Drug Repurposing in Medulloblastoma: Challenges and Recommendations
Related Experiment Video
Updated: Nov 28, 2025
Intracranial Orthotopic Allografting of Medulloblastoma Cells in Immunocompromised Mice
Published on: October 3, 2010
Hussein Hammoud1, Zahraa Saker1, Hayat Harati1
1Neuroscience Research Center, Faculty of Medical Sciences, Lebanese University, Hadas, Beirut, Lebanon.
Opinion Statement:
Medulloblastoma is the most frequently diagnosed primary malignant brain tumor among children. Currently available therapeutic strategies are based on surgical resection, chemotherapy, and/or radiotherapy. However, majority of patients quickly develop therapeutic resistance and are often left with long-term therapy-related side effects and sequelae. Therefore, there remains a dire need to develop more effective therapeutics to overcome the acquired resistance to currently available therapies. Unfortunately, the process of developing novel anti-neoplastic drugs from bench to bedside is highly time-consuming and very expensive. A wide range of drugs that are already in clinical use for treating non-cancerous diseases might commonly target tumor-associated signaling pathways as well and hence be of interest in treating different cancers. This is referred to as drug repurposing or repositioning. In medulloblastoma, drug repurposing has recently gained a remarkable interest as an alternative therapy to overcome therapy resistance, wherein existing non-tumor drugs are being tested for their potential anti-neoplastic effects outside the scope of their original use.
Insights
Drug repurposing offers a promising avenue for treating pediatric medulloblastoma, an aggressive brain cancer. This approach explores existing non-cancer drugs to overcome therapy resistance and reduce side effects.
Area of Science:
- Oncology
- Pediatric Neuro-oncology
- Pharmacology
Background:
- Medulloblastoma is the most common primary malignant brain tumor in children.
- Current treatments (surgery, chemotherapy, radiotherapy) often lead to therapeutic resistance and long-term side effects.
- Developing novel anti-cancer drugs is time-consuming and expensive.
Purpose of the Study:
- To highlight the potential of drug repurposing as an alternative therapeutic strategy for medulloblastoma.
- To address the urgent need for more effective treatments against medulloblastoma resistance.
- To explore the use of existing non-cancer drugs for their anti-neoplastic effects.
Main Methods:
- Investigating drug repurposing for medulloblastoma treatment.
- Identifying existing drugs that target tumor-associated signaling pathways.
- Evaluating the anti-neoplastic potential of repurposed drugs in medulloblastoma.
Main Results:
- Drug repurposing has emerged as a significant area of interest in medulloblastoma research.
- Existing non-cancer drugs show potential for treating medulloblastoma.
- This strategy aims to overcome acquired therapeutic resistance.
Conclusions:
- Drug repurposing presents a viable and cost-effective alternative for medulloblastoma therapy.
- Repurposed drugs may offer a way to combat treatment resistance and minimize adverse effects.
- Further research into drug repurposing is crucial for advancing pediatric brain tumor treatment.
